The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

Biomarker event

The European Cancer Patient Coalition (ECPC), together with MEP Marlene Mizzi (S&D, Malta), organised an event at the European Parliament on 5 December 2017, on the topic of Cancer Biomarkers in the Era of Personalised Medicines.

Banner

Event outline

Cancer biomarkers can be detected in bodily fluids or tissues. They can identify people who have cancer or who are at risk of getting cancer. Cancer biomarkers can also help select those people who are most likely to derive therapeutic benefit from chemotherapy, immuno-oncology therapy, surgery, or radiotherapy.  In fact, biomarkers are essential to identify the Achilles’ heel of the tumour that doctors can target with specific drugs. They can also be used to monitor remission in cancer survivors. In short, biomarkers help to identify the people who may benefit from different types of cancer treatment, ensure sustainable healthcare systems, and avoid treatment-related toxicity.

Outcomes

Read a short report on the session: https://www.news-medical.net/news/20171207/European-Cancer-Patient-Coalition-highlights-need-to-increase-access-for-genetic-and-biomarker-testing.aspx

Or download the PDF format of the report: European-Cancer-Patient-Coalition-highlights-need-to-increase-access-for-genetic-and-biomarker-testing

 

Cancer Drug Development Forum
c/o BLSI
Clos Chapelle-aux-Champs 30
1200 Brussels, Belgium

info@cddf.org
Tel: +32 2 880 62 70

Legal address
c/o Deloitte Tirol
Wirtschaftsprüfungs GmbH,
Wilhelm-Greil-Str. 15,
6020 Innsbruck, Austria